Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit Bar-Or

Showing results (131-140 of 410) with videos related to

Pageof 41
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 28, 2017
Reconstitution of the peripheral immune repertoire following withdrawal of fingolimodMahtab Ghadiri, Leslie Fitz-Gerald, Ayman Rezk, et al.
Annals of Neurology|February 29, 2008
Lesion distribution in children with clinically isolated syndromesRezwan Ghassemi, Samson B Antel, Sridar Narayanan, et al.
Biological Psychiatry|November 23, 2025
Depression as a disease of white matter network disruption: Learning from Multiple SclerosisErica B Baller, Elena C Cooper, Matthew K Schindler, et al.
Brain : a Journal of Neurology|November 18, 2025
Is multiple sclerosis-related depression different from depression in general? The data for and againstAnthony Feinstein, Amit Bar-Or, Ralph H B Benedict, et al.
Journal of Autoimmunity|February 27, 2003
CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controlsEnedina M L Oliveira, Amit Bar-Or, Alicja I Waliszewska, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2011
TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive functionMukanthu H Nyirenda, Lara Sanvito, Peter J Darlington, et al.
Neurology|March 13, 2019
Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR studyAmit Bar-Or, Richard A Grove, Jerry M Tolson, et al.
Journal of Neurology|June 26, 2013
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE studyAmit Bar-Or, Ralf Gold, Ludwig Kappos, et al.
Glia|February 21, 2003
Differential effects of Th1 and Th2 lymphocyte supernatants on human microgliaRosanne Séguin, Katarzyna Biernacki, Alexandre Prat, et al.
Journal of Neuroimmunology|March 7, 2003
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactionsKevin C O'Connor, Tanuja Chitnis, Diane E Griffin, et al.
Pageof 41

Showing results (131-140 of 410) with videos related to

Sort By:
Pageof 41
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 28, 2017
Reconstitution of the peripheral immune repertoire following withdrawal of fingolimodMahtab Ghadiri, Leslie Fitz-Gerald, Ayman Rezk, et al.
Annals of Neurology|February 29, 2008
Lesion distribution in children with clinically isolated syndromesRezwan Ghassemi, Samson B Antel, Sridar Narayanan, et al.
Biological Psychiatry|November 23, 2025
Depression as a disease of white matter network disruption: Learning from Multiple SclerosisErica B Baller, Elena C Cooper, Matthew K Schindler, et al.
Brain : a Journal of Neurology|November 18, 2025
Is multiple sclerosis-related depression different from depression in general? The data for and againstAnthony Feinstein, Amit Bar-Or, Ralph H B Benedict, et al.
Journal of Autoimmunity|February 27, 2003
CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controlsEnedina M L Oliveira, Amit Bar-Or, Alicja I Waliszewska, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2011
TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive functionMukanthu H Nyirenda, Lara Sanvito, Peter J Darlington, et al.
Neurology|March 13, 2019
Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR studyAmit Bar-Or, Richard A Grove, Jerry M Tolson, et al.
Journal of Neurology|June 26, 2013
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE studyAmit Bar-Or, Ralf Gold, Ludwig Kappos, et al.
Glia|February 21, 2003
Differential effects of Th1 and Th2 lymphocyte supernatants on human microgliaRosanne Séguin, Katarzyna Biernacki, Alexandre Prat, et al.
Journal of Neuroimmunology|March 7, 2003
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactionsKevin C O'Connor, Tanuja Chitnis, Diane E Griffin, et al.
Pageof 41